Category: News

Business Healthcare & Pharmaceuticals News

Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Late-Stage Antiviral Agent CD388

Merck MSD

Merck has announced a definitive agreement to acquire Cidara Therapeutics for approximately $9.2 billion in an all-cash deal. The strategic acquisition centers on Cidara’s lead candidate, CD388, a potentially first-in-class, long-acting antiviral designed for the universal prevention of influenza A and B, which is currently in Phase 3 trials. The transaction is expected to close in the first quarter of 2026.

Business Healthcare & Pharmaceuticals News

Merck Group Q3 2025: Strong Organic Growth Across All Sectors

Merck KGaA News

Merck delivered solid Q3 2025 results, achieving 5.2% organic growth that successfully offset significant currency headwinds. This resilience was seen across all three business sectors, driven by strong demand for Process Solutions in Life Science, the new Rare Diseases franchise in Healthcare, and AI-driven demand for Semiconductor Solutions.

Genomics Artificial Intelligence Healthcare & Pharmaceuticals News

SOPHiA GENETICS and Complete Genomics Partner to Integrate AI Oncology Assays with New Sequencing Platform

SOPHiA GENETICS NEWS

SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics have announced a collaboration to broaden access to precision oncology testing. The partnership will integrate the AI-powered SOPHiA DDMâ„¢ platform with Complete Genomics’ new DNBSEQ-T1+ sequencing system. This will provide a streamlined, sample-to-report workflow for the renowned MSK-IMPACT® (solid tumor) and MSK-ACCESS® (liquid biopsy) assays.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Roche’s Fenebrutinib Shows “Unprecedented” Phase III Success in Both Relapsing and Progressive Multiple Sclerosis

Roche

Roche announced today that its investigational oral medication, fenebrutinib, has met primary endpoints in two separate, pivotal Phase III studies for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The drug significantly reduced relapse rates in RMS and slowed disability progression in PPMS, positioning it as a potential first-in-class, high-efficacy oral treatment for the two most common forms of the disease.

Clinical Trials Healthcare & Pharmaceuticals News

Merck’s Oral PCSK9 Inhibitor, Enlicitide, Shows Significant LDL-C Reduction in Phase 3 CORALreef HeFH Trial

Merck MSD

Merck announced promising results from its pivotal Phase 3 CORALreef HeFH trial. The study found that enlicitide, an investigational, once-daily oral PCSK9 inhibitor, significantly reduced low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH). These late-breaking data were presented at the AHA Scientific Sessions 2025.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Gilead’s Trodelvy Misses Primary Goal in First-Line Breast Cancer Study, But Hope Remains for Overall Survival

Gilead

Gilead Sciences announced its Phase 3 ASCENT-07 trial for Trodelvy® in first-line HR+/HER2-negative metastatic breast cancer did not meet its primary endpoint of progression-free survival (PFS). However, the company reported an “early trend” favoring Trodelvy for the key secondary endpoint of overall survival (OS), and the study will continue to gather more data on this measure.

Clinical Trials Healthcare & Pharmaceuticals News

Eli Lilly’s Eloralintide Shows Up to 20.1% Weight Loss in Phase 2 Obesity Study

Eli Lilly and Company

Eli Lilly and Company announced positive Phase 2 trial results for eloralintide, its investigational once-weekly, selective amylin receptor agonist. The study met its primary endpoint, showing that adults with obesity or overweight achieved mean weight reductions of up to 20.1% over 48 weeks, compared to 0.4% with placebo. The drug also demonstrated a favorable tolerability profile, with mild-to-moderate gastrointestinal symptoms being the most common adverse events. Lilly plans to advance eloralintide to Phase 3 trials by the end of 2025.